[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"electric-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:electric-stimulation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100652849","stimulation-evaluation-for-neuromodulation-sensory-effects-100652849",false,"NCT07777991","Stimulation Evaluation for Neuromodulation Sensory Effects","SENSE","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Self-reported good general health, as assessed by study personnel.\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. History of epilepsy, seizure disorder, unprovoked seizure, or status epilepticus.\n3. History of febrile seizures beyond early childhood\n4. Current use of medications known to substantially lower seizure threshold, including but not limited to certain antidepressants, antipsychotics, stimulants,\n5. History of significant neurological disease, including stroke, traumatic brain injury with loss of consciousness, brain tumor, neurodegenerative disease, multiple sclerosis, or other clinically significant neurological disorders.\n6. Prior intracranial neurosurgical procedure or implanted neurostimulation device.\n7. Presence of an implanted electrical, neurostimulation, cardiac rhythm management, or other active implanted medical device.\n8. Significant scalp abnormalities that may interfere with electrode placement, including active skin disease, open wounds, infection, or severe dermatologic conditions involving the scalp.\n9. Current diagnosis of a major psychiatric disorder that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.\n10. History of severe depression associated with suicidal ideation, suicidal behavior, suicide attempt, psychiatric hospitalization for suicidality.\n11. Current suicidal ideation or behavior, as determined by participant self-report.\n12. Current substance abuse and\u002For alcohol dependence that may impair the participant's ability to safely complete study procedures.\n13. Pregnant or breastfeeding.\n14. Participation in another investigational drug, biologic, or device study within 30 days prior to enrollment, unless approved by the investigator and sponsor.\n15. History of migraine with aura, photosensitive migraine, recurrent phosphenes, visually induced neurological symptoms, or other conditions associated with heightened susceptibility to visual sensory phenomena, as determined by the investigator.\n16. History of recurrent syncope, unexplained loss of consciousness, vasovagal episodes requiring medical intervention, or other conditions associated with increased risk of fainting during medical procedures or sensory stimulation, as determined by the investigator.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn how healthy adults experience low-level electrical stimulation delivered through the study device. This study is not intended to treat a medical condition.\n\nThe main questions it aims to answer are:\n\nIs the study stimulation comfortable and well tolerated? What sensations do participants notice during stimulation? Can participants tell the difference between active stimulation and sham stimulation?\n\nResearchers will compare active stimulation with sham stimulation. Sham stimulation uses the same study procedures but does not deliver the study stimulation. This comparison will help researchers understand whether sensations are caused by stimulation rather than the study setting or expectations.\n\nParticipants will:\n\nReceive brief sessions of active and sham stimulation using the study device. Report sensations, discomfort, or other effects during and after each session. Complete questionnaires or other assessments about their experience with stimulation.\n\nThe information from this study will help researchers select stimulation settings and procedures for future studies.",[28,29,30],"Sham-controlled","Healthy Adult Participants","Electric Stimulation",[32,33,34,35,36,28,37],"Healthy volunteers","Electrical stimulation","Intersectional Short-Pulse (ISP) stimulation","Neuromodulation","Sensory effects","Noninvasive brain stimulation","NOT_YET_RECRUITING","2026-08-18",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":22},"2026-09-01",{"date":46,"type":22},"2027-09-01",{"name":48,"class":49},"Adraxe Corp.","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100590486","effectiveness-of-personalized-alternating-current-stimulation-for-treating-cognitive-impairment-in-cns-demyelination-patients-100590486","NCT06968039","Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients","This Study is Designed to Evaluate the Efficacy of Personalized Alternating Current Stimulation in the Treatment of Working Memory in Patients With Inflammatory Demyelination of the Central Nervous System","Inclusion Criteria:\n\n* Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS), and other Central Nervous System Inflammatory Demyelinating Diseases that meet diagnostic criteria;\n* Patients with SDMT scores \\\u003C55 or subjective cognitive decline;\n* Age between 18 and 65 years, gender unrestricted;\n* No relapse or medication changes in the past month;\n* EDSS (Expanded Disability Status Scale) score ≤6;\n* Right-handed, native Chinese speakers with sufficient educational background to understand the test instructions; -Willing to participate and have signed informed consent.-\n\nExclusion Criteria:\n\n* Relapse record within the past month;\n* Medication adjustment within the past month or having undergone modified electroconvulsive therapy, transcranial magnetic stimulation, or other neuromodulation techniques;\n* Participating in any other clinical research within 1 month prior to enrollment or currently;\n* Presence of cochlear hearing aids, cardiac pacemakers, or implanted brain stimulation devices;\n* Skin integrity damage at electrode placement sites, or allergy to electrode gel or adhesives;\n* History of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections;\n* Pregnant or lactating women, or those planning pregnancy in the near future;\n* Scoring ≥3 on item 3 (suicide item) of the HDRS-17 or concurrent severe mental illness;\n* Concurrent severe or unstable organic diseases;\n* Unable to cooperate with treatment, follow-up, or clinical, EEG, and imaging data collection due to poor patient compliance;\n* Other situations deemed inappropriate for study participation by the researchers.","65 Years",{"count":59,"type":22},85,[25],"Background: Central nervous system inflammatory demyelinating diseases often lead to significant cognitive impairment, presenting a critical challenge in patient management.\n\nObjective: To evaluate the effectiveness of individualized transcranial electrical stimulation (tES) in improving cognitive function among patients with inflammatory demyelinating disorders.\n\nMethods: This study will assess cognitive performance through standardized neuropsychological assessments before and after individualized a one-time tES intervention, measuring changes in cognitive domains including working memory, attention, executive function, and processing speed.\n\nAnticipated Results: We hypothesize that personalized transcranial electrical stimulation will demonstrate significant improvements in cognitive performance, potentially offering a non-invasive therapeutic approach for managing cognitive decline in central nervous system inflammatory demyelinating diseases.\n\nSignificance: This research may provide novel insights into neuromodulation strategies for cognitive rehabilitation in patients with complex neurological conditions.",[63,30],"Multiple Sclerosis","RECRUITING","2025-05-05",{"date":67,"type":42},"2025-05-13",{"date":69,"type":42},"2024-12-31",{"date":71,"type":22},"2027-10-01",{"name":73,"class":74},"Xuanwu Hospital, Beijing","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100569623","electrical-muscle-stimulation-effect-versus-myofascial-release-on-quality-of-life-in-female-fibromyalgia-100569623","NCT06696651","Electrical Muscle Stimulation Effect Versus Myofascial Release on Quality of Life in Female Fibromyalgia","Electrical Muscle Stimulation Effect Compared With Myofascial Release on Quality of Life in Female Fibromyalgia","Inclusion Criteria:\n\n1. Sixty females have diagnosed suffering from fibromyalgia syndrome.\n2. Their ages will be ranged from 45 to 55 years old.\n3. Their body mass index will be ranged from 25 to 34 ( overweight and obese type 1)\n4. They have willingness to participate in this study.\n\nExclusion Criteria:\n\n1. Peripheral vascular diseases.\n2. Drug abuse.\n3. Smokers.\n4. Chest disease. ( either obstructive or restrictive ).\n5. Clinical signs of sever cardiac events ( eg. Congestive heart disease).","FEMALE","45 Years","55 Years",{"count":87,"type":22},60,[25],"the study was done to investigate the effect of Electrical Muscle Stimulation as muscle strengthening versus the effect of myofascial releasing on quality of life in female fibromyalgia patients while following Mediterranean diet.",[30,91,92],"Myofascial Release","Fibromyalgia","2024-11-18",{"date":95,"type":42},"2024-11-20",{"date":97,"type":22},"2024-12-15",{"date":99,"type":22},"2025-03-15",{"name":101,"class":74},"Cairo University"]